LORNOXICAM-LOADED NANOSPONGES FOR CONTROLLED ANTI-INFLAMMATORY EFFECT: IN VITRO/IN VIVO ASSESSMENT

  • SEHAM M. SHAWKY Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo 11651, Egypt
  • MAHA K. A. KHALIFA Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo 11651, Egypt
  • HEBA A. EASSA Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo 11651, Egypt

Abstract

Objective: To design a controlled topical delivery system of lornoxicam (LX) in order to enhance skin permeation and treatment efficacy. Nanosponges were selected as a novel carrier for this purpose.


Methods: Nanosponges were formulated via the emulsion solvent evaporation method using ethyl cellulose (polymer) and polyvinyl alcohol (surfactant). Nanosponge dispersions were characterized for colloidal properties, entrapment efficiency and in vitro release study. The nanosponge formulation (LS1) was then incorporated into carboxymethyl cellulose sodium hydrogels and evaluated for pH, viscosity and in vitro drug release. Skin irritation was evaluated, and anti-inflammatory activity was assessed via rat hind paw edema method.


Results: Nanosponges were in the nano-sized range and attained a uniform round shape with a spongy structure. LS1exhibited the highest LX release after 6 h, so it was incorporated as hydrogel. Formulated hydrogels showed acceptable physicochemical parameters (pH, drug content and rheological properties). Skin irritation testing proved LX-loaded nanosponge hydrogel formulation (G1) to be non-irritant. In vivo study revealed an enhanced anti-inflammatory activity of G1 for 6 h (p<0.001).


Conclusion: The developed nanosponge hydrogel is an efficient nanocarrier for improved and controlled topical delivery of LX.

Keywords: Ethyl cellulose, Lornoxicam, Nanosponge, Topical delivery, Anti-inflammatory activity

References

1. Helmy HS, El-Sahar AE, Sayed RH, Shamma RN, Salama AH, Elbaz EM. Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis. Int J Nanomed 2017;12:7015-23.
2. Zaid AN, Mousa A, Jaradat N, Bustami R. Lornoxicam immediate-release tablets: formulation and bioequivalence study in healthy mediterranean volunteers using a validated LC-MS/MS method. Clin Pharmacol Drug Dev 2017;6:564-9.
3. Gadade D, Kulkarni D, Rathi P, Pekamwar S, Joshi S. Solubility enhancement of lornoxicam by crystal engineering. Indian J Pharm Sci 2017;79:277-86.
4. Nijhawan M, Santhosh A, Babu PR, Subrahmanyam CV. Solid state manipulation of lornoxicam for cocrystals—physico-chemical characterization. Drug Dev Industrial Pharm 2014;40:1163-72.
5. Marzouk M, Ammar A, Darwish M, Ali H. Preformulation, development and in vitro study of bilayer tablets of lornoxicam. Asian J Pharm Health Sci 2017;7:1769-79.
6. Dasgupta S, Ghosh SK, Ray S, Kaurav SS, Mazumder B. In vitro and in vivo studies on lornoxicam loaded nanoemulsion gels for topical application. Curr Drug Delivery 2014;11:132-8.
7. Yadav SK, Mishra MK, Tiwari A, Shukla A. EMULGEL: a new approach for enhanced topical drug delivery. Int J Curr Pharm Res 2016;9:15-9.
8. Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm (Zagreb, Croatia) 2013;63:335-58.
9. Khalifa MKA, Salem HA, Shawky SM, Eassa HA, Elaidy AM. Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients. Drug Delivery 2019;26:1243-53.
10. Shringirishi M, Prajapati SK, Mahor A, Alok S, Yadav P, Verma A. Nanosponges: a potential nanocarrier for novel drug delivery-a review. Asian Pac J Trop Dis 2014;4:S519-S26.
11. Trotta F, Dianzani C, Caldera F, Mognetti B, Cavalli R. The application of nanosponges to cancer drug delivery. Expert Opin Drug Delivery 2014;11:931-41.
12. Sujitha YS, Muzib YI. Formulation and optimization of quercetin loaded nanosponges topical gel: ex vivo, pharmacodynamic and pharmacokinetic studies. Int J Appl Pharm 2019;11:156-65.
13. Selvamuthukumar S, Anandam S, Krishnamoorthy K, Rajappan M. Nanosponges: a novel class of drug delivery system-review. J Pharm Pharm Sci 2012;15:103-11.
14. Wadhwa A, Mathura V, Lewis SA. Emerging novel nanopharmaceuticals for drug delivery. Asian J Pharm Clin Res 2018;11:35-42.
15. Aldawsari HM, Badr Eldin SM, Labib GS, El-Kamel AH. Design and formulation of a topical hydrogel integrating lemongrass-loaded nanosponges with an enhanced antifungal effect: in vitro/in vivo evaluation. Int J Nanomed 2015;10:893.
16. Ganesh R Pawbake, Satish V Shirolkar. Microemulgel: a promising approach to improve the therapeutic efficacy of drug. JCR 2020;7:1137-43.
17. Haltner Ukomadu E, Sacha M, Richter A, Hussein K. Hydrogel increases diclofenac skin permeation and absorption. Biopharm Drug Dispos 2019;40:217-24.
18. Narayanaswamy R, Torchilin VP. Hydrogels and their applications in targeted drug delivery. Molecules 2019;24:603.
19. Pushpalatha R, Selvamuthukumar S, Kilimozhi D. Cyclodextrin nanosponge based hydrogel for the transdermal co-delivery of curcumin and resveratrol: development, optimization, in vitro and ex vivo evaluation. J Drug Delivery Sci Technol 2019;52:55-64.
20. Panday P, Shukla N, Sisodiya D, Jain V, Mahajan SC. Design and characterization of microsponge loaded controlled release epicutaneous gel of lornoxicam. Appl Med Res 2015;1:16-21.
21. Bhardwaj U, Burgess DJ. Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone. Int J Pharm 2010;388:181-9.
22. Al-Suwayeh SA, Taha EI, Al-Qahtani FM, Ahmed MO, Badran MM. Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer. Sci World J 2014. https://doi.org/10.1155/2014/127495.
23. Das B, Nayak AK, Nanda U. Topical gels of lidocaine HCl using cashew gum and carbopol 940: preparation and in vitro skin permeation. Int J Biol Macromol 2013;62:514-7.
24. Osmani RAM, Kulkarni PK, Shanmuganathan S, Hani U, Srivastava A, Prerana M, et al. A 3 2 full factorial design for development and characterization of a nanosponge-based intravaginal in situ gelling system for vulvovaginal candidiasis. RSC Adv 2016;6:18737-50.
25. Gao S, Tian B, Han J, Zhang J, Shi Y, Lv Q, et al. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema. Int J Nanomed 2019;14:6135.
26. Shaikh S, Joshi YM, Kadam V. Comparative study of anti-inflammatory activity of aqueous and methanolic extracts of hibiscus cannabinus leaf (malvaceae). Int J Pharm Pharm Sci 2016;8:64-8.
27. Moin A, Deb TK, Osmani RAM, Bhosale RR, Hani U. Fabrication, characterization, and evaluation of the microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm 2016;7:39.
28. Pawar P, Gholap A, Kuchekar A, Chellam B, Mali A. Formulation and evaluation of optimized oxybenzone microsponge gel for topical delivery. J Drug Delivery 2015:1-9. Doi:10.1155/2015/261068.
29. Rajab NA, Jawad MS. Formulation and in vitro evaluation of piroxicam microsponge as a tablet. Int J Pharm Pharm Sci 2016;8:104-14.
30. Jilsha G, Viswanad V. Nanosponge loaded hydrogel of cephalexin for topical delivery. Int J Pharm Sci Res 2015;6:2781.
31. Anumolu PD, Sunitha G, Bindu SH, Satheshbabu PR, Subrahmanyam CVS. Development and validation of discriminating and biorelevant dissolution test for lornoxicam tablets. Indian J Pharm Sci 2015;77:312.
32. Neela S, Uppuluri KB. Formulation and in vitro evaluation of piroxicam loaded BSA nanospheres by desolvation. J Nanomed Nanotechnol 2015;6:1.
33. Sharma R, Pathak K. Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation. Pharm Dev Technol 2011;16:367-76.
34. Patel B, Bagade O, Ramteke K, Patel R, Awsarkar V. An assessment on preparations, characterization, and poles apart appliances of nanosponge. Int J PharmTech Res 2014;6:1898-907.
35. Bhandare CR, Katti SA. Formulation of microsponges of risperidone HCl. Int J Res Pharm Chem 2016;6:518-27.
36. Aithal PA, Mulla K, Shabaraya A. Formulation and evaluation of nanosponge based topical gel preparation of dapsone; 2019. DOI:10.13140/RG.2.2.36330.26562
37. Patel J, Patel B, Banwait H, Parmar K, Patel M. Formulation and evaluation of topical aceclofenac gel using different gelling agent. Int J Drug Dev Res 2011;3:156-64.
38. El-Assal MI. Nano-sponge novel drug delivery system as carrier of anti-hypertensive drug. Int J Pharm Pharm Sci 2019;11:47-63.
39. Abbas N, Parveen K, Hussain A, Latif S, Uz Zaman S, Shah PA, et al. Nanosponge-based hydrogel preparation of fluconazole for improved topical delivery. Trop J Pharm Res 2019;18:215-22.
Statistics
73 Views | 89 Downloads
Citations
How to Cite
SHAWKY, S. M., KHALIFA, M. K. A., & EASSA, H. A. (2020). LORNOXICAM-LOADED NANOSPONGES FOR CONTROLLED ANTI-INFLAMMATORY EFFECT: IN VITRO/IN VIVO ASSESSMENT. International Journal of Applied Pharmaceutics, 12(6), 217-223. https://doi.org/10.22159/ijap.2020v12i6.39430
Section
Original Article(s)